HUP0401170A2 - Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for - Google Patents
Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for Download PDFInfo
- Publication number
- HUP0401170A2 HUP0401170A2 HU0401170A HUP0401170A HUP0401170A2 HU P0401170 A2 HUP0401170 A2 HU P0401170A2 HU 0401170 A HU0401170 A HU 0401170A HU P0401170 A HUP0401170 A HU P0401170A HU P0401170 A2 HUP0401170 A2 HU P0401170A2
- Authority
- HU
- Hungary
- Prior art keywords
- lisinopril dihydrate
- amlodipine besylate
- weight
- microcrystalline cellulose
- sodium carboxymethyl
- Prior art date
Links
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 title claims description 40
- 229960002394 lisinopril Drugs 0.000 title claims description 37
- 238000000034 method Methods 0.000 title claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 229960000528 amlodipine Drugs 0.000 title description 8
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims description 39
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 36
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 34
- 229960004005 amlodipine besylate Drugs 0.000 claims description 32
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 29
- 239000004480 active ingredient Substances 0.000 claims description 29
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 29
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 29
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 29
- 229920000945 Amylopectin Polymers 0.000 claims description 25
- 239000011734 sodium Substances 0.000 claims description 24
- 229910052708 sodium Inorganic materials 0.000 claims description 24
- 235000019359 magnesium stearate Nutrition 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 description 23
- 238000004090 dissolution Methods 0.000 description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 13
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 12
- 235000019700 dicalcium phosphate Nutrition 0.000 description 12
- 238000005469 granulation Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 6
- 239000007857 degradation product Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- -1 2-aminoethoxy Chemical group 0.000 description 3
- 238000005243 fluidization Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- 108010007859 Lisinopril Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- KBXWAKYDYYEGBF-UHFFFAOYSA-N propan-2-ol;dihydrate Chemical compound O.O.CC(C)O KBXWAKYDYYEGBF-UHFFFAOYSA-N 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940072252 zestril Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0401170A HUP0401170A2 (en) | 2004-06-10 | 2004-06-10 | Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for |
| MEP-2010-496A ME01935B (me) | 2004-06-10 | 2005-06-09 | Farmaceutska kompozicija koja obuhvata amlodipin bezilat i lisinopril dihidrat i postupak za njihovo dobijanje |
| RS20100496A RS51677B (sr) | 2004-06-10 | 2005-06-09 | Farmaceutska kompozicija koja obuhvata amlodipin bezilat i lisinopril dihidrat i postupak za njihovo dobijanje |
| PL05751188.3T PL1765342T4 (pl) | 2004-06-10 | 2005-06-09 | Kompozycja farmaceutyczna zawierająca besylan amlodypiny i dihydrat lizynoprylu oraz sposób jej wytwarzania |
| ES05751188T ES2354618T3 (es) | 2004-06-10 | 2005-06-09 | Composición farmacéutica que comprende besilato de amlodipina y lisinopril dihidrato y procedimiento para su preparación. |
| SI200531194T SI1765342T1 (sl) | 2004-06-10 | 2005-06-09 | Farmacevtski sestavek, ki vsebuje amlodipin-bezilat in lizinopril-dihidrat, in postopek za njegovo pripravo |
| DK05751188.3T DK1765342T3 (da) | 2004-06-10 | 2005-06-09 | Farmaceutisk sammensætning omfattende amlodipinbesilat og lisinoprildihydrat og fremgangsmåde til fremstilling deraf |
| PCT/HU2005/000064 WO2005120502A1 (en) | 2004-06-10 | 2005-06-09 | New pharmaceutical composition and process for the preparation thereof |
| EP05751188A EP1765342B9 (en) | 2004-06-10 | 2005-06-09 | Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for the preparation thereof |
| DE602005024554T DE602005024554D1 (de) | 2004-06-10 | 2005-06-09 | Pharmazeutische zusammensetzung mit amlodipinbesilat und lisinoprildihydrat und herstellungsverfahren dafür |
| PT05751188T PT1765342E (pt) | 2004-06-10 | 2005-06-09 | Composição farmacêutica compreendendo besilato de amlopidina e di-hidrato de lisinopril e processo para a sua preparação |
| AT05751188T ATE486599T1 (de) | 2004-06-10 | 2005-06-09 | Pharmazeutische zusammensetzung mit amlodipinbesilat und lisinoprildihydrat und herstellungsverfahren dafür |
| EA200602187A EA010288B1 (ru) | 2004-06-10 | 2005-06-09 | Фармацевтическая композиция, содержащая амлодипина бесилат и лизиноприла дигидрат, и способ её получения |
| HR20110034T HRP20110034T1 (hr) | 2004-06-10 | 2005-06-09 | Farmaceutski sastav koji sadrži amlodipin besilat i lizinopril dihidrat te postupak njegove proizvodnje |
| HUE05751188A HUE009867T4 (hu) | 2004-06-10 | 2005-06-09 | Amlodipin-bezilátot és lizinopril-dihidrátot tartalmazó gyógyszerkészítmény és eljárás annak elõállítására |
| CY20101101203T CY1111484T1 (el) | 2004-06-10 | 2010-12-30 | Φαρμακευτικη συνθεση που περιεχει αμλοδιπινη βεσυλικη και λισινοπριλη διυδρικη και μεθοδος παρασκευης αυτης |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0401170A HUP0401170A2 (en) | 2004-06-10 | 2004-06-10 | Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HU0401170D0 HU0401170D0 (en) | 2004-08-30 |
| HUP0401170A2 true HUP0401170A2 (en) | 2006-09-28 |
Family
ID=89985289
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0401170A HUP0401170A2 (en) | 2004-06-10 | 2004-06-10 | Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for |
| HUE05751188A HUE009867T4 (hu) | 2004-06-10 | 2005-06-09 | Amlodipin-bezilátot és lizinopril-dihidrátot tartalmazó gyógyszerkészítmény és eljárás annak elõállítására |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE05751188A HUE009867T4 (hu) | 2004-06-10 | 2005-06-09 | Amlodipin-bezilátot és lizinopril-dihidrátot tartalmazó gyógyszerkészítmény és eljárás annak elõállítására |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1765342B9 (enExample) |
| AT (1) | ATE486599T1 (enExample) |
| CY (1) | CY1111484T1 (enExample) |
| DE (1) | DE602005024554D1 (enExample) |
| DK (1) | DK1765342T3 (enExample) |
| EA (1) | EA010288B1 (enExample) |
| ES (1) | ES2354618T3 (enExample) |
| HR (1) | HRP20110034T1 (enExample) |
| HU (2) | HUP0401170A2 (enExample) |
| ME (1) | ME01935B (enExample) |
| PL (1) | PL1765342T4 (enExample) |
| PT (1) | PT1765342E (enExample) |
| RS (1) | RS51677B (enExample) |
| SI (1) | SI1765342T1 (enExample) |
| WO (1) | WO2005120502A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2790817A1 (en) * | 2010-02-24 | 2011-09-01 | Sanofi-Aventis Deutschland Gmbh | Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation |
| RU2483728C1 (ru) * | 2011-09-29 | 2013-06-10 | Общество с ограниченной ответственностью "Озон" | Комбинированное гипотензивное средство и способ его получения |
| PL227900B1 (pl) * | 2012-11-15 | 2018-01-31 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję |
| CN105194647A (zh) * | 2014-06-30 | 2015-12-30 | 南京瑞尔医药有限公司 | 一种含有赖诺普利和苯磺酸氨氯地平的药物组合物及其制备方法 |
| CN106333948A (zh) * | 2016-08-23 | 2017-01-18 | 成都尚药科技有限公司 | 含有苯磺酸氨氯地平和二水合赖诺普利的药物及制备方法 |
| JP7179758B2 (ja) * | 2017-04-25 | 2022-11-29 | 大塚製薬株式会社 | 摂取可能なイベントマーカを有するリシノプリル組成物 |
| GB2595203A (en) | 2020-03-03 | 2021-11-24 | Alkaloid Ad Skopje | Formulation |
| CN119730841A (zh) * | 2022-09-07 | 2025-03-28 | 拉塞·凯那司特 | Api含量提高的氨氯地平的立即释放口服药物形式 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11500140A (ja) | 1995-03-16 | 1999-01-06 | ファイザー・インコーポレーテッド | アムロジピン、アムロジピン塩、もしくはフェロジピンとａｃｅ阻害薬とを含有する組成物 |
| HUP0202416A3 (en) | 2002-07-24 | 2006-01-30 | Richter Gedeon Vegyeszet | Novel pharmaceutical combination and it's use for the treatment of certain cardiovascular disorders |
-
2004
- 2004-06-10 HU HU0401170A patent/HUP0401170A2/hu unknown
-
2005
- 2005-06-09 AT AT05751188T patent/ATE486599T1/de active
- 2005-06-09 ME MEP-2010-496A patent/ME01935B/me unknown
- 2005-06-09 PT PT05751188T patent/PT1765342E/pt unknown
- 2005-06-09 PL PL05751188.3T patent/PL1765342T4/pl unknown
- 2005-06-09 RS RS20100496A patent/RS51677B/sr unknown
- 2005-06-09 EA EA200602187A patent/EA010288B1/ru unknown
- 2005-06-09 HU HUE05751188A patent/HUE009867T4/hu unknown
- 2005-06-09 DE DE602005024554T patent/DE602005024554D1/de not_active Expired - Lifetime
- 2005-06-09 WO PCT/HU2005/000064 patent/WO2005120502A1/en not_active Ceased
- 2005-06-09 SI SI200531194T patent/SI1765342T1/sl unknown
- 2005-06-09 HR HR20110034T patent/HRP20110034T1/hr unknown
- 2005-06-09 EP EP05751188A patent/EP1765342B9/en not_active Expired - Lifetime
- 2005-06-09 ES ES05751188T patent/ES2354618T3/es not_active Expired - Lifetime
- 2005-06-09 DK DK05751188.3T patent/DK1765342T3/da active
-
2010
- 2010-12-30 CY CY20101101203T patent/CY1111484T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005120502A1 (en) | 2005-12-22 |
| PT1765342E (pt) | 2010-12-20 |
| PL1765342T4 (pl) | 2022-11-07 |
| DE602005024554D1 (de) | 2010-12-16 |
| EA010288B1 (ru) | 2008-08-29 |
| CY1111484T1 (el) | 2015-08-05 |
| PL1765342T3 (pl) | 2011-04-29 |
| EP1765342A1 (en) | 2007-03-28 |
| ES2354618T3 (es) | 2011-03-16 |
| SI1765342T1 (sl) | 2011-02-28 |
| HUE009867T2 (enExample) | 2011-05-30 |
| EP1765342B9 (en) | 2011-02-23 |
| ME01935B (me) | 2011-10-31 |
| DK1765342T3 (da) | 2011-01-24 |
| HRP20110034T1 (hr) | 2011-02-28 |
| HUE009867T4 (hu) | 2022-01-28 |
| ATE486599T1 (de) | 2010-11-15 |
| EA200602187A1 (ru) | 2007-04-27 |
| EP1765342B1 (en) | 2010-11-03 |
| RS51677B (sr) | 2011-10-31 |
| HU0401170D0 (en) | 2004-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI109088B (fi) | Tabletti ja menetelmä sen valmistamiseksi | |
| EP1845954B1 (en) | Orally disintegrating composition of olanzapine or donepezil | |
| PT2072173E (pt) | Método de união de bases de tubos e de tubos | |
| SK114298A3 (en) | Dosage form of ibuprofen | |
| US20090232897A1 (en) | Pharmaceutical compositions comprising conjugated estrogens | |
| NZ572106A (en) | Directly compressible composite for orally disintegrating tablets | |
| US7364755B2 (en) | Modified calcium phosphate excipient | |
| PL213325B1 (pl) | Tabletka do sporzadzania zawiesin zawierajaca deferasirox oraz sposób jej wytwarzania | |
| IE913054A1 (en) | Stabilized solid chemical compositions | |
| WO2020239986A1 (en) | Pharmaceutical tablet composition comprising edoxaban | |
| HUP0401170A2 (en) | Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for | |
| EP2833871B1 (en) | Prasugrel-containing immediate release stable oral pharmaceutical compositions | |
| JP2016117738A (ja) | シロドシン−シクロデキストリン包接化合物 | |
| JP5572321B2 (ja) | 被覆微粒子含有口腔内崩壊錠 | |
| SK288240B6 (sk) | Farmaceutický prostriedok na orálne podávanie | |
| WO2000071117A1 (en) | Immediate release medicinal compositions for oral use | |
| PT1976522E (pt) | Composição farmacêutica contendo montelucaste | |
| JP6328138B2 (ja) | Ｎ−［５−［２−（３，５−ジメトキシフェニル）エチル］−２ｈ−ピラゾール−３−イル］−４−［（３ｒ，５ｓ）−３，５−ジメチルピペラジン−１−イル］ベンズアミドの医薬製剤 | |
| EP2554164B1 (en) | Pharmaceutical formulation based on ibuprofen and codeine having having improved stability | |
| PT1729735E (pt) | Processo de produção de formas de dosagens sólidas comprimidas adequado para utilização com fármacos de baixa solubilidade em água e formas de dosagens sólidas comprimidas assim obtidas | |
| HU231592B1 (hu) | Favipiravir tartalmú gyógyszerkészítmény, ennek előállítása és alkalmazása | |
| Lende et al. | Formulation development and evaluation of mouth dissolving tablet of anti-allergic drug (Astemizole) | |
| KR102488167B1 (ko) | 피롤카르복사미드의 고형 조성물 | |
| RS66409B1 (sr) | Formulacija lizinoprila i amlodipina | |
| JP2011213606A (ja) | ドネペジルを含有する固形製剤の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC9A | Change of name, address |
Owner name: RICHTER GEDEON NYRT., HU Free format text: FORMER OWNER(S): RICHTER GEDEON VEGYESZETI GYAR RT., HU |
|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |